AxD is considered a gain‐of‐function disorder in the sense that the GFAP mutations produce consequences that differ dramatically from those caused by the absence of GFAP (Brenner et al., 2009; Messing et al., 2012). The gene discussed is GFAP; the disease is Alexander disease.